WACKER BIOSOLUTIONS
In 2022, WACKER BIOSOLUTIONS grew its sales by 11.7 percent to €331.1 million (2021: €296.4 million), chiefly due to higher selling prices. Sales growth was strong in the Americas and Asia, while sales in Europe were down marginally year over year.
At €16.7 million, EBITDA was substantially lower year over year (2021: €38.6 million). Factors negatively impacting EBITDA were the temporary outage of a production facility in Burghausen, integration costs for the San Diego site in the USA and upfront costs for establishing the mRNA Competence Center in Halle. The EBITDA margin was 5.0 percent (2021: 13.0 percent).
Capital expenditures increased significantly year over year, rising from €33.5 million to €102.6 million in 2022. CapEx was focused on further expansion of the Amsterdam site and construction of the new mRNA Competence Center in Halle.
As of December 31, 2022, the number of employees at the division had increased to 835 (Dec. 31, 2021: 751 ).
|
|
|
|
|
||||||
€ million |
|
2022 |
|
2021 |
|
2020 |
|
2019 |
|
2018 |
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Total sales |
|
331.1 |
|
296.4 |
|
246.1 |
|
243.0 |
|
227.0 |
EBITDA |
|
16.7 |
|
38.6 |
|
38.1 |
|
31.1 |
|
23.5 |
EBITDA margin (%) |
|
5.0 |
|
13.0 |
|
15.5 |
|
12.8 |
|
10.4 |
EBIT |
|
-4.7 |
|
20.7 |
|
21.6 |
|
14.0 |
|
9.8 |
Capital expenditures |
|
102.6 |
|
33.5 |
|
19.9 |
|
13.2 |
|
17.9 |
R&D expenses |
|
4.8 |
|
5.6 |
|
5.7 |
|
6.4 |
|
6.3 |
Employees (December 31, number) |
|
835 |
|
751 |
|
764 |
|
754 |
|
709 |
